Surveillance of influenza in Iceland during the 2009 pandemic

Sigmundsdóttir, Guðrún; Guðnason, Þórólfur; Ólafsson, Ö; Baldvinsdóttir, Guðrún Erna; Atladottir, A; Löve, Arthur; Danon, León; Bríem, Haraldur

doi:10.2807/ese.15.49.19742-en

Cited by 16 publications

(27 citation statements)

References 10 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are consistent with our estimates of H1N1pdm seroprevalence using post-pandemic sera and with other H1N1pdm seroprevalence studies recently or not yet published from Iceland, Mexico, Chinese Taipei, India, Mongolia, Mali, [53][54][55][56] Laos, Djibouti, and Bolivia (CoPanFlu-International consortium unpublished data, personal communication from X. de Lamballerie), with a study from Tables S1-S3 for studies included in each estimate.…”

Section: Discussionsupporting

confidence: 92%

Estimating age‐specific cumulative incidence for the 2009 influenza pandemic: a meta‐analysis of A(H1N1)pdm09 serological studies from 19 countries

Kerkhove¹,

Hirve

Koukounari

et al. 2013

Influenza Resp Viruses

164

139

View full text Add to dashboard Cite

BackgroundThe global impact of the 2009 influenza A(H1N1) pandemic (H1N1pdm) is not well understood.ObjectivesWe estimate overall and age‐specific prevalence of cross‐reactive antibodies to H1N1pdm virus and rates of H1N1pdm infection during the first year of the pandemic using data from published and unpublished H1N1pdm seroepidemiological studies.MethodsPrimary aggregate H1N1pdm serologic data from each study were stratified in standardized age groups and evaluated based on when sera were collected in relation to national or subnational peak H1N1pdm activity. Seropositivity was assessed using well‐described and standardized hemagglutination inhibition (HI titers ≥32 or ≥40) and microneutralization (MN ≥ 40) laboratory assays. The prevalence of cross‐reactive antibodies to the H1N1pdm virus was estimated for studies using sera collected prior to the start of the pandemic (between 2004 and April 2009); H1N1pdm cumulative incidence was estimated for studies in which collected both pre‐ and post‐pandemic sera; and H1N1pdm seropositivity was calculated from studies with post‐pandemic sera only (collected between December 2009–June 2010).ResultsData from 27 published/unpublished studies from 19 countries/administrative regions – Australia, Canada, China, Finland, France, Germany, Hong Kong SAR, India, Iran, Italy, Japan, Netherlands, New Zealand, Norway, Reunion Island, Singapore, United Kingdom, United States, and Vietnam – were eligible for inclusion. The overall age‐standardized pre‐pandemic prevalence of cross‐reactive antibodies was 5% (95%CI 3–7%) and varied significantly by age with the highest rates among persons ≥65 years old (14% 95%CI 8–24%). Overall age‐standardized H1N1pdm cumulative incidence was 24% (95%CI 20–27%) and varied significantly by age with the highest in children 5–19 (47% 95%CI 39–55%) and 0–4 years old (36% 95%CI 30–43%).ConclusionsOur results offer unique insight into the global impact of the H1N1 pandemic and highlight the need for standardization of seroepidemiological studies and for their inclusion in pre‐pandemic preparedness plans. Our results taken together with recent global pandemic respiratory‐associated mortality estimates suggest that the case fatality ratio of the pandemic virus was approximately 0·02%.

show abstract

Section: Discussionsupporting

confidence: 92%

Estimating age‐specific cumulative incidence for the 2009 influenza pandemic: a meta‐analysis of A(H1N1)pdm09 serological studies from 19 countries

Kerkhove¹,

Hirve

Koukounari

et al. 2013

Influenza Resp Viruses

164

139

View full text Add to dashboard Cite

show abstract

“…Као последица ранијег прокуживања вирусом грипа најстарије популације, резултати нашег истраживања показују да је највећи број оболелих у све три сезоне праћења у узрасту од 5 до 14 година а најмањи у узрасту преко 65 година, што је у складу са резултатима других земаља током пандемијске године надзора над грипом [7][8][9] .…”

Section: дискусијаunclassified

Results of influenza surveillance during the pandemic and post-pandemic influenza season in AP Vojvodina, Serbia

Ristić¹,

Seguljev²,

Petrović³

et al. 2014

Opsta med

View full text Add to dashboard Cite

“…While the classification of this novel influenza virus as a pandemic strain has been debated [Cohen and Carter, 2010;Evans, 2010;Tang et al, 2010], it has prompted a reassessment of recent pandemic preparedness practices [Cordova-Villalobos et al, 2009;Del Rio and Hernandez-Avila, 2009;del Rio and Guarner, 2010;Rizzo et al, 2010;Tay et al, 2010]. An important lesson identified in many retrospective studies was the importance of collecting, analyzing and disseminating high quality surveillance data for informing diagnostic, therapeutic and public health interventions [Cordova-Villalobos et al, 2009;Kumar et al, 2010;Rizzo et al, 2010;Sigmundsdottir et al, 2010;Tay et al, 2010].…”

Section: Introductionmentioning

confidence: 99%

A Universal Influenza A and B Duplex Real‐time RT‐PCR Assay

Lee

Loh

Lee

et al. 2012

Journal of Medical Virology

View full text Add to dashboard Cite

A high throughput universal influenza A and B duplex real-time RT-PCR was developed to meet effectively the heightened surveillance and diagnostic needs essential in managing influenza infections and outbreaks. Primers and probes, designed to target highly conserved regions of the matrix protein of influenza A and the nucleoprotein of influenza B, were optimized using the high-throughput LightCycler 480 II system. Analytical sensitivity and specificity were characterized using RNA transcripts diluted serially, archived non-influenza respiratory viruses, and proficiency test samples. Eighty-nine clinical samples were tested in parallel against existing influenza A and B monoplex assays. Once validated, the duplex assay was applied prospectively on 2,458 clinical specimens that were later subtyped. In April 2011, the emergence of an influenza B variant necessitated the inclusion of an additional modified probe for influenza B and revalidation of the revised protocol. The lower detection limits of the assay were 50 copies/PCR. There was no cross-reactivity against any non-influenza respiratory virus and all proficiency testing materials were identified correctly. The parallel testing revealed a 98.9% overall agreement. Routine application of the assay revealed high sensitivity and specificity for the detection of influenza A/H1N1/2009, A/H3N2 and influenza B. Assay C(q) values correlated well between the pre- and post-revision protocols for influenza A (r(2) = 0.998) and B (r(2) = 0.999). The revised protocol detected three additional novel influenza B variant cases in 200 specimens reported previously as influenza B negative. This in-house assay offers a highly sensitive and specific option for laboratories seeking to expand their influenza testing capacity.

show abstract

Surveillance of influenza in Iceland during the 2009 pandemic

Abstract: Binary file ES_Abstracts_Final_ECDC.txt matches

Cited by 16 publications

References 10 publications

Estimating age‐specific cumulative incidence for the 2009 influenza pandemic: a meta‐analysis of A(H1N1)pdm09 serological studies from 19 countries

Estimating age‐specific cumulative incidence for the 2009 influenza pandemic: a meta‐analysis of A(H1N1)pdm09 serological studies from 19 countries

Results of influenza surveillance during the pandemic and post-pandemic influenza season in AP Vojvodina, Serbia

A Universal Influenza A and B Duplex Real‐time RT‐PCR Assay

Contact Info

Product

Resources

About